VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, is pleased to see the positive and encouraging outcomes from the MAPS Phase 3 MDMA-Assisted Therapy (MDMA-AT) Clinical Trial published today on Nature Medicine. The Company considers the results to be a substantial…


Previous articleSecond Phase 3 Study of MDMA-assisted Therapy Reports Positive Results, Paving Way for New Drug Application
Next articlePT442 – Burning Questions About Burning Man: Mud, Ebola, and the Big Krab Car